tiprankstipranks
Genmab risk/reward favorable into arbitration ruling, says Morgan Stanley
The Fly

Genmab risk/reward favorable into arbitration ruling, says Morgan Stanley

Morgan Stanley analyst Matthew Harrison names Genmab (GMAB) a "Catalyst Driving Idea" while keeping an Underweight rating on the shares with a $34 price target. Genmab and Johnson & Johnson (JNJ) are in a second arbitration over Darzalex Faspro and a ruling is expected in 2023. The analyst reviewed the redacted copy of the license agreement and believes Genmab "may have a valid claim." The license agreement states that the milestone payments and royalties are paid on a licensed product-by-licensed product basis, and for each licensed product, royalty payments shall commence on the date of the first commercial sale of such licensed product and expiring on the later of 13 years thereafter or the expiration of relevant patents, Harrison tells investors in a research note. He says the key issue is whether Genmab is entitled to additional milestone payments and a new 13-year royalty term from Darzalex Faspro’s first commercial sale date. Harrison views Genmab’s risk/reward as favorable into the 2023 ruling.

Published first on TheFly

See Insiders’ Hot Stocks on TipRanks >>

Read More on GMAB:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles